Cargando…
Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients
BACKGROUND: Ingenol mebutate (IM), a novel agent for field therapy of actinic keratosis (AK), has a drawback of inducing local skin reactions (LSRs), which may cause discomfort in patients. To reduce the LSRs, we tried the application of IM in low amounts. OBJECTIVE: The purpose of this study was to...
Autores principales: | Joe, Hyun Jae, Oh, Byung Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384689/ https://www.ncbi.nlm.nih.gov/pubmed/28408848 http://dx.doi.org/10.2147/CCID.S129072 |
Ejemplares similares
-
Ingenol mebutate: A novel topical drug for actinic keratosis
por: Aditya, Suruchi, et al.
Publicado: (2013) -
New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel
por: Berman, Brian
Publicado: (2012) -
Ingenol mebutate treatment in actinic keratosis – clinical effectiveness and potential side effects
por: Lesiak, Aleksandra, et al.
Publicado: (2019) -
Efficacy of ingenol mebutate gel for actinic keratosis in patients treated by thiazide diuretics
por: Campione, Elena, et al.
Publicado: (2016) -
Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp
por: Skroza, Nevena, et al.
Publicado: (2017)